The effect of thalidomide on visceral fat pad mass and triglyceride concentration of the skeletal muscles in rats

다국어 초록 (Multilingual Abstract)

Background: Body fats, especially both of abdominal fat pad mass and skeletal muscle fat content, are inversely related to insulin action. Therefore, methods for decreasing visceral fat mass and muscle triglyceride content may be helpful for the prevention of insulin resistance.
Methods: Thalidomide, used for its anti-angiogenic and anti-inflammatory properties, was administered to rats for 4 weeks. A 10% solution of thalidomide in dimethyl sulfoxide was injected daily into the peritoneal cavity as much as 100 mg/kg of body weight.
Results: The total visceral fat pad mass in the thalidomide-treated group was 11% lower than in the control group. The size of adipocytes of the epididymal fat pad mass in the thalidomide-treated group was smaller than in the control group. The intraperitoneal thalidomide treatment increased triglyceride concentrations by 16% in the red muscle, but not in the white muscle.
Conclusion: The results suggested that intraperitoneal thalidomide treatment inhibited abdominal fat accumulation, and that the free fatty acids in the blood were preferentially accumulated in the red muscle rather than in the white muscle.

참고문헌 (Reference)

1 Haslett P, "The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus" 13 : 1047-1054, 1997

2 Yabu T, "Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate" 106 : 125-134, 2005

3 D'Amato RJ, "Thalidomide is an inhibitor of angiogenesis" 91 : 4082-4085, 1994

4 Nakamitsu PZ, "Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice" 15 : 151-158, 2015

5 Frayn KN, "Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability" 21 : 139-144, 1980

6 Teo SK, "Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs" 59 : 160-168, 2001

7 Korach-André M, "Relationship between visceral adiposity and intramyocellular lipid content in two rat models of insulin resistance" 288 : E106-E116, 2005

8 Fukumura D, "Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis" 93 : e88-e97, 2003

9 Kelley DE, "Muscle triglyceride and insulin resistance" 22 : 325-346, 2002

10 Krssak M, "Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study" 42 : 113-116, 1999

11 Kim JY, "Insulin resistance of muscle glucose transport in male and female rats fed a high-sucrose diet" 276 : R665-R672, 1999

12 Hua N, "Influence of muscle fiber type composition on early fat accumulation under high-fat diet challenge" 12 : e0182430-, 2017

13 Kim JY, "High-fat diet-induced muscle insulin resistance:relationship to visceral fat mass" 279 : R2057-R2065, 2000

14 Hall JE, "Guyton and Hall textbook of medical physiology" Elsevier 84-, 2016

15 Denton RM, "Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion" 104 : 416-422, 1967

16 Jacob S, "Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects" 48 : 1113-1119, 1999

17 Rupnick MA, "Adipose tissue mass can be regulated through the vasculature" 99 : 10730-10735, 2002

18 Folch J, "A simple method for the isolation and purification of total lipides from animal tissues" 226 : 497-509, 1957